Printer Friendly

Antimicrobial Drug Prescription and Neisseria gonorrhoeae Susceptibility, United States, 2005-2013.

Neisseria gonorrhoeae, the causative pathogen of gonorrhea, has been designated an urgent antimicrobial drug resistance threat by the Centers for Disease Control and Prevention (CDC) (1). Since the introduction of antimicrobial drugs in the first half of the 20th century, N. gonorrhoeae has successively developed resistance to each antimicrobial agent recommended for gonorrhea treatment (2). In the United States, the prevalence of resistance in N. gonorrhoeae often varies by sex of partner and by geographic region (3,4). Prevalence is often greater in isolates from gay, bisexual, and other men who have sex with men (MSM) than those from men who have sex only with women (MSW), and prevalence is often highest in the West and lowest in the South (4). Resistant strains, in particular penicillinase-producing N. gonorrhoeae, fluoroquinolone-resistant N. gonorrhoeae (PPNG), and gonococcal strains with reduced cephalosporin susceptibility, seemed to emerge initially in the West (Hawaii and the West Coast) before spreading eastward across the country (5-9). These geographic patterns seem to support the idea that importation of resistant strains from other regions of the world, such as eastern Asia, is a primary factor of the emergence of resistant gonococci in the United States (5-9). Whereas antimicrobial drug prescribing patterns have been clearly associated with the emergence of resistance in other bacterial pathogens, the degree to which domestic antimicrobial use and subsequent selection pressure contributes to the emergence of gonococcal antimicrobial resistance in the United States is unclear (10-13). Using an ecologic approach, we sought to investigate the potential geographic and temporal association between antimicrobial drug susceptibility among US N. gonorrhoeae isolates and domestic outpatient antimicrobial drug prescribing rates in the United States during 2005-2013.

Methods

Data Sources

We used data from 3 sources: N. gonorrhoeae antimicrobial drug susceptibility data from the Gonococcal Isolate Surveillance Project (GISP), antimicrobial drug consumption data from IMS Health, and US Census data for population denominators. GISP is a CDC-supported sentinel surveillance system that has monitored gonococcal antimicrobial susceptibility in the United States since 1987 (4). GISP includes selected publicly funded sexually transmitted infection (STI) clinics in 25-30 cities and 4-5 regional laboratories each year. Each month, up to 25 N. gonorrhoeae urethral samples are collected consecutively from men with gonococcal urethritis attending participating STI clinics; these samples are submitted to regional laboratories for antimicrobial drug susceptibility testing according to a common protocol (4). Sampling men with gonococcal urethritis is an efficient means to detect gonococcal infections: urethral infections in men are likely to be symptomatic (prompting patients to seek healthcare), and gonococcal urethritis can be rapidly diagnosed by Gram stain (4). In addition, sampling of men allows for monitoring of susceptibility among infections in MSM and heterosexual sexual networks (4).

We abstracted deidentified epidemiologic data from medical records. When analyzing data, we limited the number of isolates to [less than or equal to] 300/city/year to minimize overrepresentation of individual cities; we chose isolates at random for removal from the analytic dataset when >300 isolates were submitted from a site in a year. Gonococcal isolates collected at each clinic are subcultured at the clinic's local public health laboratory on supplemented chocolate medium and frozen in trypticase soy broth containing 20% glycerol. Isolates are shipped monthly to 1 of the regional laboratories for [beta]-lactamase production testing and agar dilution antimicrobial drug susceptibility testing. From 2005 through 2013, the testing panel consistently included azithromycin, ceftriaxone, ciprofloxacin, penicillin, spectinomycin, and tetracycline. Cefixime susceptibility testing was conducted from 2005 through 2006, temporarily halted in 2007 due to lack of availability of cefixime in the United States, and resumed in 2009. Cefpodoxime susceptibility testing was conducted from 2009 through 2012. Standardized bacterial suspensions are inoculated on Difco GC Medium Base supplemented with 1% IsoVitaleX Enrichment (Becton, Dickinson and Company Diagnostic Systems, Sparks, MD, USA).

For antimicrobial drug prescribing data, we extracted QuintilesIMS (Danbury, CT, USA) data on systemic oral antimicrobial drug prescriptions dispensed in the United States during 2005-2013. During the study period, Quintiles-IMS captured >70% of all outpatient prescriptions in the United States, reconciled them to wholesale deliveries, and projected to 100% coverage of all prescription activity using a patented projection method based on a comprehensive sample of patient-deidentified prescription transactions (collected from pharmacies that report their entire pharmacy business to the company each week) (14). These data represent outpatient prescriptions across all payers and include county of prescriber (used in this analysis); data are from community pharmacies and federal government and nongovernmental mail service pharmacies. The IMS projection method standardizes these data into estimated prescription counts and uses geospatial methods to align the estimated prescriptions for the non-sample pharmacies to prescribers with observed prescribing behaviors for the same product in nearby sample pharmacies. The method is routinely validated at various levels of granularity by IMS Health statistical and analytic teams (15). We obtained population data on age, sex, and county from US Census bridged-race population estimates published by the CDC.

Data Analysis

We restricted the analysis to GISP sites that participated continuously from 2005 through 2013. We focused on azithromycin, cefixime, ceftriaxone, and ciprofloxacin because these agents are currently recommended for gonorrhea treatment (azithromycin and ceftriaxone), are in the same antimicrobial class as a recommended antimicrobial drug (cefixime), or are widely used for outpatient treatment of non-STD infections or are of renewed interest because of potential novel diagnostics for detection of resistance determinants (ciprofloxacin) (16,17). We calculated geometric mean MICs and the percentage of isolates with resistance or reduced susceptibility for each antimicrobial drug by GISP site and year. Per Clinical and Laboratory Standards Institute criteria, we categorized ciprofloxacin resistance as MIC [greater than or equal to] 1 [micro]g/mL (18). In the absence of established resistance breakpoints for other antimicrobial drugs of interest, we categorized reduced cefixime susceptibility as [greater than or equal to] 0.25 [micro]g/mL, reduced ceftriaxone susceptibility as [greater than or equal to] 0.125 [micro]g/mL, and reduced azithromycin susceptibility as [greater than or equal to] 2.0 [micro]g/mL.

Using IMS data for each county corresponding to each of the 23 included GISP sites, we summarized antimicrobial drug prescription counts by specific antimicrobial drug (azithromycin, cefixime, ceftriaxone, and ciprofloxacin) and aggregated antimicrobial category (macrolides, cephalosporins, and fluoroquinolones). To reflect the sex and age distribution of men with gonorrhea sampled in GISP, we limited the antimicrobial drug prescription counts to prescriptions to men 10-59 years of age. We calculated prescription rates for the aggregated antimicrobial drug categories (defined as the number of prescriptions per 1,000 men 10-59 years of age) by county and year using US Census data for denominators. Using the prescribing rate for each antimicrobial category by county and year, we calculated the median prescribing rate for each county across years. The degree of overlap between the county and catchment area of the corresponding STD clinic is expected to be somewhat imprecise and vary by geographic site: some clinic catchment areas may include a small section of a large county, whereas other catchment areas may extend beyond the borders of the corresponding county.

We performed linear regression analyses in which the dependent variable was antimicrobial susceptibility (geometric mean MIC) at each GISP site and the independent variable of interest was the prior year prescription rate (i.e., the prescribing rate during the year before the year corresponding to the antimicrobial drug susceptibility results) at each county and year. We considered 2 representations of the prescribing rate variable: the original lag variable and the centered lag variable (19,20). We used the noncentered lag variable to calculate the results. We performed separate longitudinal models for each drug by geometric mean MIC and the rate of prescribing of the corresponding antimicrobial class (azithromycin susceptibility and macrolide prescribing; cefixime and ceftriaxone susceptibility and cephalosporin prescribing; and ciprofloxacin susceptibility and fluoroquinolone prescribing) (19,20). We performed exploratory analyses to determine if there was a linear relationship between the susceptibility outcome and time. The linear assumption was satisfied, so we did not perform any transformation. To examine the association between susceptibility outcomes and prescribing rate, we then constructed multivariable linear mixed models for repeated measures with intercept and time as random effects. The models included 3 potential confounders based on a priori decisions (as these variables have been found to be associated with antimicrobial drug prescribing and/or gonococcal susceptibility): geographic region; sex of sex partner (defined as the percentage of MSM at each GISP site per year, based on GISP data); and race (defined as the percentage of men with urethral gonorrhea who were black or African American at each GISP site per year, based on GISP data) (3,4,15,21). We conducted all analyses in SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA), using Proc Mixed for restricted maximum-likelihood estimation for small size samples. We calculated CIs at a = 0.05 to determine statistically significant associations.

Results

Antimicrobial Susceptibility

Of 33 GISP sites that participated at some point during 2005 through 2013, 23 participated continuously and were included. From these sites, 44,957 isolates were collected and submitted to GISP (range per site in a given year 49-393) and, after removal of observations if >300 isolates were submitted by a site in a year, we included data from 43,852 (97.5%) isolates in the analysis. The percentage of gonococcal isolates with reduced cefixime susceptibility increased from 0.1% in 2005 to 1.6% in 2011 and decreased to 0.5% by 2013 (Table 1). Overall, geometric mean cefixime MICs increased slightly from 2006 to 2009 and then remained stable. The percentage of isolates with reduced ceftriaxone susceptibility increased slightly from 2005 to 2011 and then decreased; the geometric mean increased slightly from 2006 to 2007 and then remained stable. The percentage of isolates with reduced azithromycin susceptibility varied between 0.2% and 0.6%; the geometric mean appeared to peak in 2008 and increased again during 2011-2013. The percentage of isolates with ciprofloxacin resistance increased during 2005-2007 and increased again during 2009-2013; the geometric mean MIC increased during 2005-2013. For each antimicrobial drug, geometric mean MICs varied by site and year (online Technical Appendix Tables 1-4, 8, https://wwwnc.cdc.gov/EID/article/23/10/17-0488-Techapp1.pdf). Sites with the highest median cefixime and ciprofloxacin geometric mean MICs were in the West; those with the lowest were in the South and Midwest (online Technical Appendix Tables 1, 4). Sites with highest median azithromycin geometric means were in the Midwest and West, and those with the lowest were in the South (online Technical Appendix Table 3). We found little variation in median ceftriaxone geometric mean MICs across sites (online Technical Appendix Table 2).

Antimicrobial Drug Use

Counties with the highest cephalosporin, macrolide, and fluoroquinolone prescribing rates, such as Jefferson County, Alabama, and Oklahoma County, Oklahoma, were located in the South (online Technical Appendix Tables 5-7). Counties with the lowest prescribing rates, such as Multnomah County, Oregon, and San Diego and San Francisco, California, were located in the West. Cephalosporin prescribing rates increased in many counties but decreased in sites such as those in Honolulu, Hawaii, and Los Angeles, California (online Technical Appendix Table 5). During 2005-2013, macrolide prescribing increased in all counties (online Technical Appendix Table 6). Fluoroquinolone prescribing increased in most counties, with the largest absolute increases occurring in counties in the South (online Technical Appendix Table 7). The multivariable models did not demonstrate associations between N. gonorrhoeae susceptibility and antimicrobial drug prescribing for any of the studied antimicrobial drugs (Table 2).

Discussion

Using an ecologic approach, we did not find an association between population-level outpatient prescribing rates of clinically relevant antimicrobial drugs and N. gonorrhoeae antimicrobial drug susceptibility among urethral isolates from men in the United States. Prescribing rates were lowest in sites both where ciprofloxacin resistance and reduced cefixime susceptibility initially emerged and where the prevalence of resistance or reduced susceptibility has been highest, such as Honolulu, Hawaii, and West Coast sites (4,22,23). Conversely, prescribing rates are highest in the southern United States, the region where the prevalence of gonococcal resistance has tended to be the lowest (4).

Bacterial antimicrobial drug resistance is clearly broadly linked to antimicrobial drug use, but the association is probably complex, interacting through several possible mechanisms and varying by bacteria, mode of transmission, antimicrobial drug, prevalence of resistance, and geographic location (24). For some bacterial pathogens, such as Streptococcus pneumoniae and Escherchia coli, associations between population-level antimicrobial drug prescribing and resistance in the United States and Europe have been described (10-13). We did not find such an association for N. gonorrhoeae.

There are at least 2 possible explanations for the apparent lack of county-level association between domestic antimicrobial drug prescribing and N. gonorrhoeae susceptibility. First, factors other than population-level prescribing rates, such as importation of resistant strains from other countries, might contribute to emergence of gonococcal resistance in the United States. Previously published epidemiologic data have strongly suggested that resistant strains, such as PPNG and fluoroquinolone-resistant N. gonorrhoeae, and strains with reduced cefixime susceptibility (also investigated with genomic data), emerged initially in other parts of the world, particularly eastern Asia, and subsequently spread to the United States through Hawaii and the West Coast (5-9).

Second, it is possible that our data sources, methodology, or both lacked sufficient sensitivity to detect an association. The time period analyzed might have played a role: antimicrobial drug prescribing could conceivably be of greater or lesser importance during different phases of the emergence or persistence of resistance. As an inherent limitation of an ecologic approach, it is also possible that the prescribing rates we used in our analysis do not necessarily reflect antimicrobial drug use patterns among persons at risk for gonorrhea. For example, men seeking care in publicly funded STI clinics may be underinsured and thus lack access to routine medical care and be less likely to receive antimicrobial drug prescriptions. On the other hand, men diagnosed with gonorrhea in STI clinics may have been exposed to repeated antimicrobial drug courses for repeated STIs. Antimicrobial drug use might differ between MSM and MSW, so the availability of population-level drug prescribing data that include the sex of sex partners would be helpful.

Future investigations of associations between antimicrobial drug use and gonococcal susceptibility may also be strengthened by the availability of the indication for treatment (not available in the QuintilesIMS data), allowing for analyses linking susceptibility to antimicrobial drug use specifically for gonorrhea treatment. Investigators have previously identified links between individuallevel antimicrobial drug use and gonococcal resistance in the United States (25,26). Nearly 30 years ago, Zenilman et al. found that persons with gonorrhea in Dade County, Florida, who had medicated themselves with illicit antibacterial drugs were more likely to be infected with PPNG than penicillin-sensitive strains (odds ratio 3.6; 95% CI 1.9-6.8) (25). Of note, our dataset does not include illicit or nonprescribed antimicrobial drugs. Among persons with gonorrhea in California during 2000-2003, antimicrobial drug use in the 3 months before diagnosis with gonorrhea was independently associated with infection with a fluoroquinolone-resistant strain (26). Using multisite GISP data for 2005-2010, we previously found that recent antimicrobial drug use was independently associated with N. gonorrhoeae ciprofloxacin, penicillin, and tetracycline resistance among men with gonococcal urethritis (3). However, the magnitude of the association between resistance and antimicrobial drug use was dwarfed by the magnitude of the association between resistance and geographic region and sex of sex partner, and use of an antimicrobial drug was not associated with reduced susceptibility to azithromycin, cefixime, and ceftriaxone.

The antimicrobial drugs that clinicians choose to treat gonorrhea may influence the susceptibility of N. gonorrhoeae populations. In the early 1970s, an increase in the recommended dosage of penicillin in response to increased resistance was followed by a plateau in penicillin resistance; experts speculated that the updated and highly effective treatment schedule retarded the selection of resistant mutants (27). Recently, cephalosporin susceptibility in the United States appeared to improve following updates in CDC treatment guidelines that recommended routine dual therapy, a preference for injectable ceftriaxone over oral cefixime, and a higher ceftriaxone dose (28). In contrast, some gonorrhea treatment approaches might promote resistance. Treatment with azithromycin alone is not recommended because of concerns about the ease with which N. gonorrhoeae can develop macrolide drug resistance; previously published cases seem to illustrate selection of higher azithromycin MICs following gonorrhea treatment with azithromycin monotherapy (29-31). Spectinomycin resistance was observed to emerge rapidly among US service members stationed in South Korea after spectinomycin was adopted as the primary gonorrhea treatment by the US military (following the emergence of PPNG) (32).

Emergence and persistence of gonococcal-resistant phenotypes is probably influenced by a complex (and not yet fully understood) interplay of bacterial and host factors, such as the ease with which the gonococcal strain can acquire necessary mutation(s); the effect of the mutation(s) on bacterial fitness; the anatomic site of infection (which can influence symptomatology, likelihood of treatment success, and coexistence of N. gonorrhoeae with other bacteria with which DNA may be shared); host mobility (including international travel); host sexual behavior; the nature of the sexual network within which the resistant strain emerges; prevalence of resistance; provider screening practices; and antimicrobial drug exposure (32-37). Furthermore, the relative importance of each factor may differ by resistance phenotype. The framework posited by Lipsitch and Samore may prove useful for considering mechanisms by which antimicrobial drugs might contribute to N. gonorrhoeae resistance, such as emergence of resistance during treatment or clearance of a susceptible majority bacterial population and subsequent transmission of a resistant minority population (24,29). However, much work remains to be done to understand these complex relationships.

Our analysis has other limitations. Ecologic analyses are limited by the potential for unmeasured and uncontrolled confounding. Conclusions of this ecologic analysis are based on counties or geographic site, rather than individual patients. Prescribing data were derived from counties that in some instances do not fully overlap with the STD clinic catchment areas from which the susceptibility data were derived. Our analyses were limited to data from men. However, the inclusion of data from women is unlikely to have influenced the results: women may consume more antimicrobial drugs than men, and gonococcal isolates from women tend to be more susceptible to antimicrobial drugs than those from men (similar to isolates from MSW and substantially more susceptible than isolates from MSM) (38,39). An important caveat is that our findings are only applicable to the United States: they should not be extrapolated to other countries and regions. It is possible that rates of population-level antimicrobial drug prescribing or use in other countries may select for resistant gonococcal strains, which in turn may spread across international borders. Further investigation to understand region- or county-specific factors contributing to resistance is urgently needed.

The findings of our analysis suggest that population-wide domestic antimicrobial drug prescribing rates might not play a prominent role in the emergence of gonococcal resistance in the United States. Other means, such as importation from other countries, might play larger roles. Through this lens, enhanced surveillance for and public health capacity to respond to imported resistant strains are important strategies. However, it is possible that the choice of antimicrobial drugs that clinicians prescribe for gonorrhea therapy might influence the persistence or spread of resistant gonococcal strains that emerge in the United States. US-based healthcare providers should treat gonorrhea according to CDC STI treatment guidelines with dual therapy of 250 mg ceftriaxone as a single intramuscular dose plus 1 g azithromycin orally (16). The remarkable ability of N. gonorrhoeae to develop resistance to each antimicrobial drug used for treatment (2), combined with the declining number of new drugs (40), highlight the need to develop and apply interventions to slow the emergence and spread of gonococcal resistance.

Dr. Kirkcaldy is the team lead of the Epidemiology Research Team in the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA. His research interests include STI epidemiology, antimicrobial drug resistance in bacterial STIs, and gonorrhea treatment.

References

(1.) Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013 [cited 2017 May 2]. http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf

(2.) Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol. 2012;7:1401-22. http://dx.doi.org/10.2217/fmb.12.117

(3.) Kirkcaldy RD, Zaidi A, Hook EW III, Holmes KK, Soge O, del Rio C, et al. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005-2010. Ann Intern Med. 2013;158:321-8. http://dx.doi.org/10.7326/0003-4819-158-5-201303050-00004

(4.) Kirkcaldy RD, Harvey A, Papp JR, Del Rio C, Soge OO, Holmes KK, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance--The Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014. MMWR Surveill Summ. 2016;65(No. SS-7):1-19. http://dx.doi.org/10.15585/mmwr.ss6507a1

(5.) Jaffe HW, Biddle JW, Johnson SR, Wiesner PJ. Infections due to penicillinase-producing Neisseria gonorrhoeae in the United States: 1976-1980. J Infect Dis. 1981;144:191-7. http://dx.doi.org/10.1093/infdis/144.2.191

(6.) Trees DL, Sandul AL, Neal SW, Higa H, Knapp JS. Molecular epidemiology of Neisseria gonorrhoeae exhibiting decreased susceptibility and resistance to ciprofloxacin in Hawaii, 1991-1999. Sex Transm Dis. 2001;28:309-14. http://dx.doi.org/10.1097/00007435-200106000-00001

(7.) Iverson CJ, Wang SA, Lee MV, Ohye RG, Trees DL, Knapp JS, et al. Fluoroquinolone resistance among Neisseria gonorrhoeae isolates in Hawaii, 1990-2000: role of foreign importation and increasing endemic spread. Sex Transm Dis. 2004;31:702-8. http://dx.doi.org/10.1097/01.olq.0000145846.45781.a4

(8.) Wang SA, Lee MV, O'Connor N, Iverson CJ, Ohye RG, Whiticar PM, et al. Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime--Hawaii, 2001. Clin Infect Dis. 2003;37:849-52. http://dx.doi.org/10.1086/377500

(9.) Grad YH, Kirkcaldy RD, Trees D, Dordel J, Harris SR, Goldstein E, et al. Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study. Lancet Infect Dis. 2014;14:220-6. http://dx.doi.org/10.1016/S1473-3099(13)70693-5

(10.) Hicks LA, Chien YW, Taylor TH Jr, Haber M, Klugman KP; Active Bacterial Core Surveillance (ABCs) Team. Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis. 2011; 53:631-9. http://dx.doi.org/10.1093/cid/cir443

(11.) Bronzwaer SL, Cars O, Buchholz U, Molstad S, Goettsch W, Veldhuijzen IK, et al.; European Antimicrobial Resistance Surveillance System. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis. 2002;8:278-82. https://wwwnc.cdc.gov/eid/article/8/3/01-0192_article

(12.) van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, et al.; European Antimicrobial Resistance Surveillance System Group; European Surveillance of Antimicrobial Consumption Project Group. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis. 2008;14:1722-30. http://dx.doi.org/10.3201/eid1411.070467

(13.) Riedel S, Beekmann SE, Heilmann KP, Richter SS, Garcia-de-Lomas J, Ferech M, et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis. 2007;26:485-90. http://dx.doi.org/10.1007/s10096-007-0321-5

(14.) Boardman C. inventor; IMS Health Incorporated, assignee. System and method for estimating product distribution using a product specific universe. United States patent US 7174304. 2007 Feb 6.

(15.) Hicks LA, Bartoces MG, Roberts RM, Suda KJ, Hunkler RJ, Taylor TH Jr, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis. 2015;60:1308-16.

(16.) Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137.

(17.) Hemarajata P, Yang S, Soge OO, Humphries RM, Klausner JD. Performance and verification of a real-time PCR assay targeting the gyrA gene for prediction of ciprofloxacin resistance in Neisseria gonorrhoeae. J Clin Microbiol. 2016;54:805-8. http://dx.doi.org/10.1128/JCM.03032-15

(18.) Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-sixth informational supplement (M100-S26). Wayne (PA): The Institute; 2016.

(19.) Raudenbush SW, Bryk AS. Hierarchical linear models: applications and data analysis methods. 2nd ed. Thousand Oaks (CA): Sage Publications; 2002.

(20.) Singer JD, Willett JB. Applied longitudinal data analysis: modeling change and event occurrence. Oxford/New York: Oxford University Press; 2003.

(21.) Fleming-Dutra KE, Shapiro DJ, Hicks LA, Gerber JS, Hersh AL. Race, otitis media, and antibiotic selection. Pediatrics. 2014;134:1059-66. http://dx.doi.org/10.1542/peds.2014-1781

(22.) Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae--Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep. 2002;51:1041-4.

(23.) Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2013: Gonococcal Isolate Surveillance Project (GISP) supplement and profiles cited [cited 2017 May 2]. http://www.cdc.gov/std/gisp2013/gisp-2013-all-profiles.pdf

(24.) Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis. 2002;8:347-54. https://wwwnc.cdc.gov/eid/article/8/4/01-0312_article

(25.) Zenilman JM, Bonner M, Sharp KL, Rabb JA, Alexander ER. Penicillinase-producing Neisseria gonorrhoeae in Dade County, Florida: evidence of core-group transmitters and the impact of illicit antibiotics. Sex Transm Dis. 1988;15:45-50. http://dx.doi.org/10.1097/00007435-198801000-00011

(26.) Bauer HM, Mark KE, Samuel M, Wang SA, Weismuller P, Moore D, et al. Prevalence of and associated risk factors for fluoroquinolone-resistant Neisseria gonorrhoeae in California, 2000-2003. Clin Infect Dis. 2005;41:795-803. http://dx.doi.org/10.1086/432801

(27.) McCormack WM. Treatment of gonorrhea--is penicillin passe? N Engl J Med. 1977;296:934-6. http://dx.doi.org/10.1056/ NEJM197704212961610

(28.) Kirkcaldy RD, Hook EW III, Soge OO, del Rio C, Kubin G, Zenilman JM, et al. Trends in Neisseria gonorrhoeae susceptibility to cephalosporins in the United States, 2006-2014. JAMA. 2015;314:1869-71. http://dx.doi.org/10.1001/jama.2015.10347

(29.) Soge OO, Harger D, Schafer S, Toevs K, Raisler KA, Venator K, et al. Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011). Sex Transm Dis. 2012;39:877-9. http://dx.doi.org/10.1097/OLQ.0b013e3182685d2b

(30.) Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. Int J STD AIDS. 1997;8:299-302. http://dx.doi.org/10.1258/0956462971920127

(31.) Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill. 2011;16:19833.

(32.) Boslego JW, Tramont EC, Takafuji ET, Diniega BM, Mitchell BS, Small JW, et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med. 1987;317:272-8. http://dx.doi.org/10.1056/NEJM198707303170504

(33.) Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387:176-87. http://dx.doi.org/10.1016/S0140-6736(15)00473-0

(34.) Kunz AN, Begum AA, Wu H, D'Ambrozio JA, Robinson JM, Shafer WM, et al. Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. J Infect Dis. 2012;205:1821-9. http://dx.doi.org/ 10.1093/infdis/jis277

(35.) Weinstock H, Workowski KA. Pharyngeal gonorrhea: an important reservoir of infection? Clin Infect Dis. 2009;49:1798-800. http://dx.doi.org/10.1086/648428

(36.) Ameyama S, Onodera S, Takahata M, Minami S, Maki N, Endo K, et al. Mosaic-like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother. 2002;46:3744-9. http://dx.doi.org/10.1128/AAC.46.12.37443749.2002

(37.) Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex Transm Dis. 1995;22:39-47. http://dx.doi.org/10.1097/ 00007435-199501000-00007

(38.) Frenk SM, Kit BK, Lukacs SL, Hicks LA, Gu Q. Trends in the use of prescription antibiotics: NHANES 1999-2012. J Antimicrob Chemother. 2016;71:251-6. http://dx.doi.org/ 10.1093/jac/dkv319

(39.) Kidd S, Moore PC, Kirkcaldy RD, Philip SS, Wiesenfeld HC, Papp JR, et al. Comparison of antimicrobial susceptibility of urogenital Neisseria gonorrhoeae isolates obtained from women and men. Sex Transm Dis. 2015;42:434-9. http://dx.doi.org/10.1097/OLQ.0000000000000312

(40.) Shlaes DM, Sahm D, Opiela C, Spellberg B. The FDA reboot of antibiotic development. Antimicrob Agents Chemother. 2013;57:4605-7. http://dx.doi.org/10.1128/AAC.01277-13

Address for correspondence: Robert D. Kirkcaldy, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop E02, Atlanta, GA 30329-4027, USA; email: rkirkcaldy@cdc.gov

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (R.D. Kirkcaldy, M.G. Bartoces, J.R. Papp, L.A. Hicks); University of Washington, Seattle, Washington, USA (O.O. Soge); Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA (S. Riedel); Texas Department of State Health Services, Austin, Texas, USA (G. Kubin); Emory University, Atlanta (C. Del Rio); University of Alabama at Birmingham, Birmingham, Alabama, USA (E.W. Hook III)

DOI: https://doi.org/10.3201/eid2310.170488
Table 1. Antimicrobial drug resistance and reduced susceptibility in
gonococcal isolates by drug, Gonococcal Isolate Surveillance Project,
United States, 2005-2013 *

Results ([dagger])            Cefixime   Ceftriaxone

2005
  Geometric mean MIC           0.009        0.006
  Reduced susceptibility, %     0.1          0.1
2006
  Geometric mean MIC           0.010        0.005
  Reduced susceptibility, %     0.1          0.1
2007
  Geometric mean MIC             NT         0.010
  Reduced susceptibility, %      --          0.1
2008
  Geometric mean MIC             NT         0.010
  Reduced susceptibility, %      --          0.1
2009
  Geometric mean MIC           0.020        0.010
  Reduced susceptibility, %     0.9          0.3
2010
  Geometric mean MIC           0.020        0.010
  Reduced susceptibility, %     1.6          0.4
2011
  Geometric mean MIC           0.020        0.010
  Reduced susceptibility, %     1.6          0.4
2012
  Geometric mean MIC           0.020        0.010
  Reduced susceptibility, %     1.0          0.3
2013
  Geometric mean MIC           0.021        0.010
  Reduced susceptibility, %     0.5          0.1

Results ([dagger])            Azithromycin   Ciprofloxacin

2005
  Geometric mean MIC             0.189           0.011
  Reduced susceptibility, %       0.6            10.1
2006
  Geometric mean MIC             0.204           0.016
  Reduced susceptibility, %       0.3            15.4
2007
  Geometric mean MIC             0.240           0.027
  Reduced susceptibility, %       0.5            16.0
2008
  Geometric mean MIC             0.242           0.024
  Reduced susceptibility, %       0.2            14.7
2009
  Geometric mean MIC             0.192           0.031
  Reduced susceptibility, %       0.3            10.8
2010
  Geometric mean MIC             0.174           0.039
  Reduced susceptibility, %       0.6            14.2
2011
  Geometric mean MIC             0.171           0.039
  Reduced susceptibility, %       0.3            14.4
2012
  Geometric mean MIC             0.183           0.042
  Reduced susceptibility, %       0.3            16.1
2013
  Geometric mean MIC             0.202           0.043
  Reduced susceptibility, %       0.6            17.1

* Results are for 23 sites that participated in GISP for the entire
study period. Cefixime MIC testing range was 0.001-0.5 [micro]/mL
during 2005-2006 and 0.015-0.5 [micro]g/mL during 2009-2013;
ceftriaxone MIC testing range was 0.001-2.0 [micro]g/mL during
2005-2006 and 0.008-2.0 [micro]g/mL during 2007-2013; azithromycin
MIC testing range was 0.008-16 [micro]g/mL during 2005-2006 and
0.03-16 [micro]g/mL during 2007-2013; ciprofloxacin MIC testing
range was 0.001-16 [micro]g/mL during 2005-2006 and 0.008-16
[micro]g/mL during 2007-2013. NT, not tested.

([dagger]) Reduced susceptibility indicates isolate's resistance or
reduced susceptibility to the indicated drug. Reduced cefixime
susceptibility was defined as MIC [greater than or equal to] 0.25
[micro]g/ml, reduced ceftriaxone susceptibility MIC [greater than
or equal to] 0.125 [micro]g/mL, reduced azithromycin susceptibility
MIC [greater than or equal to] 2 [micro]g/mL, and ciprofloxacin
resistance defined as MIC [greater than or equal to] 1 [micro]g/mL.

Table 2. Adjusted linear regression coefficients for change in
antimicrobial geometric mean MIC associated with 10% increase in
corresponding antimicrobial prescribing rate for 23 sites, Gonococcal
Isolate Surveillance Project, United States, 2005-2013 *

Effect                    [beta]        SE     d.f.      95% CI of
                        coefficient                        [beta]
                                                        coefficient
Azithromycin
  Time                    -0.0087     0.003    155    -0.0146, -0.0029
  Macrolide               -0.0155     0.002    155    -0.0502, 0.0191
    prescribing
    ([dagger])
Cefixime
  Time                    0.0011      0.0001   109     0.0008, 0.0014
  Cephalosporin           0.0016      0.0013   109    -0.0010, 0.0041
    prescribing
    ([double dagger])
Ceftriaxone
  Time                    0.0004      0.0001   155     0.0002, 0.0005
  Cephalosporin           0.0002      0.0006   155    -0.0009, 0.0013
    prescribing
    ([double dagger])
Ciprofloxacin
  Time                    0.0004      0.0021   155    -0.0038, 0.0045
  Fluoroquinolone         0.0004      0.0230   155    -0.0451, 0.0458
    prescribing
    ([section])

* All models were adjusted for percent of MSM at each site (using
GISP data), race (percentage of men coded as black versus non-black
in GISP data), percentage, and geographic region. Time was based on
1-year intervals. Estimate is statistically significant if the 95%
CI of [beta] coefficient does not cross 0.

([dagger]) Per 10% increase in macrolide prescribing during the
previous year; includes azithromycin, clarithromycin, and
erythromycin.

([double dagger]) Per 10% increase in cephalosporin prescribing
during the previous year; includes cefaclor, cefadroxil, cefdinir,
cefditoren pivoxil, cefixime, cefpodoxime proxetil, cefprozil,
ceftibuten, cefuroxime axetil, cephalexin, cephradine, and
loracarbef.

([section]) Per 10% increase in fluoroquinolone prescribing during
the previous year; includes ciprofloxacin, gemifloxacin,
levofloxacin, moxifloxacin, norfloxacin, ofloxacin, and
trovafloxacin.
COPYRIGHT 2017 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RESEARCH
Author:Kirkcaldy, Robert D.; Bartoces, Monina G.; Soge, Olusegun O.; Riedel, Stefan; Kubin, Grace; Del Rio,
Publication:Emerging Infectious Diseases
Article Type:Report
Geographic Code:1USA
Date:Oct 1, 2017
Words:5584
Previous Article:Economic Assessment of Waterborne Outbreak of Cryptosporidiosis.
Next Article:Poliovirus Excretion in Children with Primary Immunodeficiency Disorders, India.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters